The Zhitong Finance App learned that before the US stock market on Tuesday, Johnson & Johnson (JNJ.US) announced better-than-expected results for the third quarter of 2026 and raised revenue and profit guidelines for the full year 2026. Financial reports show that Johnson & Johnson's third-quarter sales increased 5.9% year over year to US$25.4 billion, in line with general market expectations. In terms of profit, GAAP net profit plummeted 95.9% year over year to US$210 million. After dilution, earnings per share were only 0.09 US dollars (2.12 US dollars in the same period last year), mainly due to one-time pre-tax expenses related to the proposed settlement of the US$5,519 billion talc lawsuit.
Excluding one-time items and amortization of intangible assets, etc., the adjusted net profit was US$6.339 million; the adjusted earnings per share were US$2.59, exceeding the market's consensus expectation of about US$2.53, but it was still down 7.5% year-on-year (US$2.80 for the same period last year); and the operating adjusted earnings per share was US$2.61.
On the business side, Innovative Medicine's revenue was US$16.757 billion, up 7.7% year over year. Core product performance differentiation: Darzalex's revenue increased 15.4% year over year to US$4.239 billion; revenue of the self-exempt drug Tremfya increased 68.3% year over year to US$2,396 million, exceeding market expectations of about US$2.19 billion); revenue of the psychiatric drug Carvykti increased 35.5% year over year to US$710 million; Stelara's revenue fell 54.4% year over year to US$716 million due to the impact of generic drugs, but still exceeded market expectations of about US$591 million due to dose structure optimization.
The medical device business (MedTech) revenue was $8.642 billion, up 2.5% year over year. Chief Financial Officer Joe Wolk said that the Middle East conflict, European market tightening, and China's pricing pressure have caused a “more obvious” drag on international medical device sales, and that the Abiomed ventricular assist pump business is still affected by Impella research in the UK earlier this year. R&D investment increased 26.7% year-on-year to US$4.652 billion, and R&D intensity increased to 18.3% from 15.3% in the same period last year.
In terms of guidance, Johnson & Johnson raised the median sales revenue guide for the full year of 2026, from about US$101.1 billion to US$101.2 billion (range of US$1010-101.4 billion), and the adjusted median earnings per share guidance was raised from US$11.04 to US$11.10 (range of 11.05 to 11.15 US dollars), all higher than the agreed market expectations. CEO Joaquin Duato said the “momentum for accelerated growth” continued this quarter, and the company is “more clear on the path to achieving double-digit growth by the end of this decade,” but did not give specific figures for 2027.
In terms of operating performance, in the third quarter, OTTAVA's soft tissue robotic surgery system was approved by the FDA, and the new drug Imaaivy (nipocalimab) was approved by the FDA for warm-antibody autoimmune hemolytic anemia; the company completed the acquisition of Firefly Bio and reached an IN vivo CAR-T cooperation with Sail BioMedications; Jennifer Taubert retired, and Tom Cavanaugh became the global chairman of the innovative drug business.